Kanakinumab: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
←Membuat halaman berisi '{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 460015774 | image = Canakinumab bound to IL-1β.png | alt = | type = mab | caption = Ribbon diagram of canakinumab (blue) bound to IL-1β (yellow) from PDB entry {{PDBe|5bvp}}<ref>{{cite journal | vauthors = Rondeau JM, Ramage P, Zurini M, Gram H | title = The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody...' Tag: halaman dengan galat kutipan Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: halaman dengan galat kutipan Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 87:
Efek samping yang umum termasuk infeksi (pilek dan infeksi saluran pernapasan atas), nyeri perut, dan reaksi di tempat suntikan.<ref name="Ilaris FDA label" /><ref name="Ilaris EPAR" /><ref name="FDA PR 20200616" />
==Sejarah==
==Efek samping==
==Referensi==
{{Reflist}}
== Pranala luar ==
* {{cite web | title=Canakinumab | website=National Cancer Institute | url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795723 }}
[[Category:Antineoplastic drugs]]
[[Category:Drugs developed by Novartis]]
[[Category:Monoclonal antibodies]]
| |||